Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Decera Clinical Education Infectious Disease Podcast

If RSV Vaccines Are Approved for Older Adults, What’s Next?

02 Nov 2022

Description

An RSV vaccine, if approved, may reduce disease burden in older adults. In this recap of the most common questions from a symposium at the Family Medicine Experience 2022 conference, listen as we discuss when an RSV vaccine may be approved and how to overcome barriers to the implementation of vaccines for older adults in primary care settings.Hear answer to questions such as:When might potential RSV vaccines be available, and when might the Advisory Committee on Immunization Practices make recommendations on their use?How will the vaccine roll out? Who would receive the vaccine first?If approved, what will the RSV vaccination schedule be?How can we overcome vaccine hesitancy?PresentersJohn J. Russell, MD, FAAFPClinical Professor of Family and Community MedicineSidney Kimmel College of MedicineThomas Jefferson UniversityPhiladelphia, PennsylvaniaChair, Department of Family and Community MedicineAbington-Jefferson HealthAbington, PennsylvaniaLaura Hurley, MD, MPHAssociate Professor of MedicineDivision of General Internal MedicineDepartment of MedicineUniversity of Colorado Anschutz Medical CampusAurora, ColoradoPrimary Care PhysicianDivision of General Internal MedicineDepartment of MedicineDenver HealthDenver, ColoradoPamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganView the full program at:https://bit.ly/3Wt87GI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.